Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Centre Hospitalier Universitaire De Nantes has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. This distribution across 2 distinct art units indicates that the company patent portfolio covers a variety of technical subjects. Such a spread requires the legal team to adapt to different examination standards across the patent office.
The prosecution involves 2 distinct examiners, meaning that each pending matter is being reviewed independently. This lack of concentration ensures that the 2 pending office actions are not subject to the same potential bottlenecks. However, it also requires managing separate timelines and sets of examiner preferences.
CUNNINGCHEN, KATHLEEN MARY is the busiest examiner for this portfolio, currently overseeing 1 pending office action. While this examiner handles a portion of the workload, the total of 2 pending office actions is split among the distinct examiners. Practitioners should monitor the 1 pending office action under this examiner while also addressing the other active matter in the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
| BATES, KEENAN ALEXANDER | 1 | 44.9% | +79.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251809 | METHODS FOR THE DIAGNOSIS AND THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | CUNNINGCHEN, KATHLEEN MARY | — |
| 17625902 | CHEMICALLY-MODIFIED ADENO-ASSOCIATED VIRUS | BATES, KEENAN ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251809 | METHODS FOR THE DIAGNOSIS AND THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | CUNNINGCHEN, KATHLEEN MARY | — |
| 17625902 | CHEMICALLY-MODIFIED ADENO-ASSOCIATED VIRUS | BATES, KEENAN ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18251809 | METHODS FOR THE DIAGNOSIS AND THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103§112 | Final Rejection | — | Pending | May 04, 2023 |
| 17625902 | CHEMICALLY-MODIFIED ADENO-ASSOCIATED VIRUS | BATES, KEENAN ALEXANDER | 1631 | §103§112 | Non-Final OA | — | Pending | Jan 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentre Hospitalier Universitaire De Nantes has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kathleen Mary Cunningchen has the most, with 1 of Centre Hospitalier Universitaire De Nantes's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
